Innoviva, Inc. (INVA): Price and Financial Metrics

Innoviva, Inc. (INVA): $12.96

0.21 (+1.65%)

POWR Rating

Component Grades













Add INVA to Watchlist
Sign Up

Industry: Biotech



in industry


  • INVA scores best on the Value dimension, with a Value rank ahead of 97.84% of US stocks.
  • The strongest trend for INVA is in Quality, which has been heading up over the past 179 days.
  • INVA ranks lowest in Sentiment; there it ranks in the 10th percentile.

INVA Stock Summary

  • With a price/earnings ratio of 3.02, INNOVIVA INC P/E ratio is greater than that of about just 3.94% of stocks in our set with positive earnings.
  • Of note is the ratio of INNOVIVA INC's sales and general administrative expense to its total operating expenses; just 0.31% of US stocks have a lower such ratio.
  • For INVA, its debt to operating expenses ratio is greater than that reported by just 0.35% of US equities we're observing.
  • If you're looking for stocks that are quantitatively similar to INNOVIVA INC, a group of peers worth examining would be CRK, EQT, CPG, WPM, and PXS.
  • INVA's SEC filings can be seen here. And to visit INNOVIVA INC's official web site, go to

INVA Valuation Summary

  • INVA's price/sales ratio is 2.3; this is 54.9% lower than that of the median Healthcare stock.
  • Over the past 223 months, INVA's price/sales ratio has gone down 125.1.

Below are key valuation metrics over time for INVA.

Stock Date P/S P/B P/E EV/EBIT
INVA 2023-01-30 2.3 1.4 3.0 2.9
INVA 2023-01-27 2.4 1.4 3.0 2.9
INVA 2023-01-26 2.4 1.4 3.0 2.9
INVA 2023-01-25 2.3 1.4 3.0 2.9
INVA 2023-01-24 2.3 1.4 3.0 2.9
INVA 2023-01-23 2.4 1.4 3.1 3.0

INVA Growth Metrics

    The year over year net income to common stockholders growth rate now stands at -25.91%.
  • Its 2 year cash and equivalents growth rate is now at -38.41%.
  • Its 5 year cash and equivalents growth rate is now at 120.25%.
Over the past 33 months, INVA's revenue has gone up $112,200,000.

The table below shows INVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 373.216 291.208 292.58
2022-06-30 403.821 372.229 99.495
2022-03-31 396.407 377.808 187.504
2021-12-31 391.866 363.813 265.854
2021-12-31 391.866 363.813 265.854
2021-09-30 374.662 350.712 309.412

INVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INVA has a Quality Grade of B, ranking ahead of 77.13% of graded US stocks.
  • INVA's asset turnover comes in at 0.398 -- ranking 118th of 682 Pharmaceutical Products stocks.
  • LUMO, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with INVA.

The table below shows INVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.398 1 0.357
2021-06-30 0.385 1 0.331
2021-03-31 0.353 1 0.337
2020-12-31 0.375 1 0.336
2020-09-30 0.389 1 0.354
2020-06-30 0.390 1 0.363

INVA Price Target

For more insight on analysts targets of INVA, see our INVA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 2.5 (Moderate Sell)

INVA Stock Price Chart Interactive Chart >

Price chart for INVA

INVA Price/Volume Stats

Current price $12.96 52-week high $20.71
Prev. close $12.75 52-week low $11.56
Day low $12.74 Volume 556,802
Day high $13.02 Avg. volume 605,359
50-day MA $13.09 Dividend yield N/A
200-day MA $13.97 Market Cap 904.39M

Innoviva, Inc. (INVA) Company Bio

Innoviva is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders. The company was founded in 1996 and is based in South San Francisco, California.

INVA Latest News Stream

Event/Time News Detail
Loading, please wait...

INVA Latest Social Stream

Loading social stream, please wait...

View Full INVA Social Stream

Latest INVA News From Around the Web

Below are the latest news stories about INNOVIVA INC that investors may wish to consider to help them evaluate INVA as an investment opportunity.

12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds

In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […]

Yahoo | January 23, 2023

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement (the "credit agreement") with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross p

Yahoo | January 10, 2023

Innoviva (INVA) Gains As Market Dips: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.

Yahoo | January 3, 2023

7 Undervalued Biotech Stocks to Buy Before They Boom

While medical innovations offer tremendous appeal, investors can still get a discount in this sector via undervalued biotech stocks to buy.

Josh Enomoto on InvestorPlace | December 29, 2022

Innoviva (INVA) Stock Moves -1.06%: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day.

Yahoo | December 28, 2022

Read More 'INVA' Stories Here

INVA Price Returns

1-mo -2.34%
3-mo -0.15%
6-mo -10.25%
1-year -20.15%
3-year -9.37%
5-year -9.94%
YTD -2.19%
2022 -23.19%
2021 39.23%
2020 -12.50%
2019 -18.85%
2018 22.97%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.771 seconds.